anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pain related to a tendon, termed tendinopathy, can be traumatic or insidious in onset and short-lasting or persistent in nature. Tendinopathy is common musculoskeletal condition; the incidence of tendinopathy is higher than osteoarthritis, for example. Achilles tendinopathy (AT) affects both active and sedentary individuals and can be characterised by reduced activity tolerance to specific tasks that load the tendon. This results in decreased activity participation such as walking, running and working.

Current clinical guidelines recommend exercise as the first line treatment for people with Achilles tendinopathy. However, the rate and extent of improvement in pain and disability varies. This variation suggests the investigators need to understand what factors predict change so the investigators can enhance care provided. Previously it was suggested that exercise worked by improving the strength or structure of the tendon, but it has been reported that pain and disability can change without corresponding changes in strength or structure. This suggests that other factors might be important predictors.

Recent literature suggests cognitive and contextual influences such as self-efficacy, working alliance and expectations may be important factors for predicting change in pain and disability in tendinopathy and need investigation. Based on this need, high-quality research is warranted. To inform the development of this research, two recent studies have been undertaken. Firstly, a feasibility study was completed. This study aimed to understand if it was feasible to collect data using a secure website to explore the association and predictive relationship of working alliance, outcome expectations and self-efficacy with pain and disability in the management of AT. The second study was a process evaluation to gain insight into the procedures undertaken in the feasibility study. Seven patients were interviewed to discover what worked (and did not) from their perspective during the study. Based on the results from the feasibility study and the information from the interviews with patients, using this website is feasible, but the investigators have made some changes before proposing this larger study. These changes include better promotion of the study, how verbal recruitment strategies could be improved, and how communication between clinicians and researchers could be made better. Based upon this knowledge this proposal aims to understand if working alliance, patient outcome expectations and self-efficacy predict response to treatment for AT.
Lumbar disc herniation and bulging are two pathological types of disc disease. Due to long-term, chronic and repeated accumulated strain and degenerative change of lumbar intervertebral discs, nucleus pulposus and annulus fibrosus can be reduced in moisture, fragile in texture, small in height, increased in activity of annulus fibrosus, and even cracked. The nucleus pulposus tissue and the fibers with increased mobility can also bulge around, which is called lumbar disc bulging. The nucleus pulposus tissue can protrude into the vertebral canal through the weak points and fissures of the annulus fibrosus to press nerve roots of the corresponding segment, causing numbness, pain, weakness, etc. of the lower limbs, which is called lumbar disc herniation. Lumbar disc herniation is a disease which many people have, and the disease has a long course and is relatively difficult to treat. And may also cause other physical pain. Such as lumbago, leg pain, etc. The invention relates to a traditional Chinese medicine wine for treating lumbar disc herniation.
Valproate can cause fetal harm when administered to a pregnant woman. Pregnancy registry data show that maternal valproate use can cause neural tube defects and other structural abnormalities (e.g., craniofacial defects, cardiovascular malformations and malformations involving various body systems). The rate of congenital malformations among babies born to mothers using valproate is about four times higher than the rate among babies born to epileptic mothers using other anti-seizure monotherapies. Evidence suggests that folic acid supplementation prior to conception and during the first trimester of pregnancy decreases the risk for congenital neural tube defects in the general population. 

Several published epidemiological studies have indicated that children exposed to valproate in utero have lower cognitive test scores than children exposed to either another antiepileptic drug in utero or to no antiepileptic drugs in utero. The largest of these studies is a prospective cohort study conducted in the United States and United Kingdom that found that children with prenatal exposure to valproate had lower Differential Ability Scale (D.A.S.) scores at age 3 (92 [95% C.I. 88-97]) than children with prenatal exposure to the other antiepileptic drug monotherapy treatments evaluated: lamotrigine (101 [95% C.I. 98-104]), carbamazepine (98 [95% C.I. 95-102]) and phenytoin (99 [95% C.I. 94 - 104]). The D.A.S., which has a mean score of 100 (SD = 15), is a battery of cognitive tests designed for children ages 2.5 to 17 years. The D.A.S. is a measure of neurobehavioral development performed when children are too young to undergo IQ testing and generally correlates with IQ scores later in childhood. 

Although all of the available studies have methodological limitations, the weight of the evidence supports the conclusion that valproate exposure in utero causes subsequent adverse effects on cognitive development. 

In animal studies, valproate-exposed offspring had malformations similar to those seen in humans and demonstrated behavioral deficits [see Use in Specific Populations (8.1)].
BACKGROUND: Ferroptosis was reported to possess the therapeutic potentials in various human cancers. In the present study, we explored the expression, clinical significance and the molecular mechanism of FK506 binding protein 3 (FKBP3) in the progression of lung adenocarcinoma (LUAD).
MATERIAL AND METHOD: Cox regression was performed to obtain the prognosis related to differentially expressed genes (DEGs) in LUAD datasets from TCGA. We also downloaded the ferroptosis-related gene datasets from GeneCards. Venn diagram was performed to find the intersecting genes and FKBP3 was selected as the targeted gene by analyzing the diagnostic and prognostic values of Top10 intersecting genes. Moreover, univariate and multivariate analyses were performed to evaluate the association between clinicopathological factors and survival rates. GO/KEGG and GSEA analysis was performed to explore the function of FKBP3 in LUAD progression. Protein-protein interaction (PPI) network was performed via STRING database and the top10 hub genes were selected. Finally, the relationship between FKBP3 and immune infiltration was explored by ssGSEA analysis.
RESULTS: Firstly, 184 genes associated with the prognosis of LUAD and ferroptosis were obtained. FKBP3 was found to be significantly associated with a poor overall survival rate of LUAD patients. Immunohistochemical staining results showed that FKBP3 was highly located in cytoplasm and membrane of cells in LUAD tissues. PPI network analysis results showed that HDAC1, YY1, HDAC2, MTOR, PSMA3, PIN1, NCL, C14orf166, PIN4, and LARP6 were the top10 hub genes. Furthermore, spearman analysis results showed that the expression of FKBP3 was positively correlated with the abundance of Th2 cells and T helper cells.
CONCLUSION: High level of FKBP3 was associated with poor prognostic outcomes of LUAD patients, which also inhibited immune infiltration in LUAD tissues. Additionally, FKBP3 was involved in regulating the ferroptosis process in LUAD patients. Thus, FKBP3 possessed the tumor promotion role might be involving in regulating ferroptosis and immune infiltration in LUAD progression.
Hypoglycemia is a clinical marker of carnitine deficiency. Thus carnitine may compound the risk of hypoglycemia for children on insulin therapy. Currently, one of the limitations in the management of diabetes is hypoglycemia. The problem of hypoglycemia is of even greater significance in the pediatric population because children have smaller glycogen stores.

In this study, we will determine if there is a group of children with increased frequency of hypoglycemia and carnitine deficiency. If there is a correlation from the initial 200 children, we will compare two groups of type I diabetic children between the ages of 7 to 21 years. We will take 20 children with the highest carnitine levels (found in a previous study) and 20 children with the lowest carnitine levels and perform continuous glucose monitoring for a 72-hour period. Those who have at least one episode of hypoglycemia will be asked to undergo repeat testing, after a 2-week period of oral carnitine supplementation. Supplementation will start at 50 mg/kg body weight for the first week and then increase to 100 mg/kg body weight the second week. Laboratory studies obtained at baseline include Hemoglobin A1c, carnitine panel, and lipid panel. These will be repeated prior to the second continuous glucose monitoring. Insulin doses will not be changed between glucose monitoring sessions. A comparison will be made between individuals with hypoglycemia, to see if the number of hypoglycemic events has decreased.
With improvements in antenatal and neonatal care over the last 20 years, now infants are born as early as 22 weeks gestation and survive to discharge from hospital. This increased survival comes with increased risk of long term issues such as cerebral palsy and chronic lung disease. There is strong evidence to show these risks are increased due to an underlying inflammatory process initiated around the time of premature birth. This study aims to prove the safety of treating infants born between 24-27+6 weeks gestation with Anakinra, a medication which is similar to an anti-inflammatory molecule the body makes itself called Interleukin 1 Receptor Antagonist (IL-1Ra). Anakinra acts to reduce the inflammatory response and is currently used in adults and children as young as 8 months to manage autoimmune inflammatory conditions. This study looks at the safety of giving Anakinra to babies born extremely premature, over the first 3 weeks of life. Once safety is established, the investigators will conduct a larger trial studying the efficacy of this treatment for reducing the risk of long-term complications caused by neonatal inflammation in extremely preterm infants.
FIELD: food-production and cosmetics industry. SUBSTANCE: biologically-active additive contains germanium-organic compound of pyridine acid C 42 H 24 N 6 O 11 Ge 3  and can be used in production of food-stuffs for example juices, sauces, phytobalsams, and also in cosmetics industry for production of various creams, lipsticks, lotions, cosmetic milk, etc. Application of aforesaid biologically-active additive allows for inducing immune interferon, activating macrophagal and phagocytic links in human organism. In addition, biologically-active additive possesses high activity, it normalizes metabolic processes and also allows for widening range of biological-active additives. EFFECT: higher efficiency. 8 cl, 4 ex
PURPOSE:To prepare the titled safe surface antigen in mass, by using a recombinant obtained by inserting a surface antigen gene for synthesizing surface antigen into the metabolic enzyme gene of vector DNA having metabolic enzyme gene. CONSTITUTION:A DNA donor comprising the DNA of hepatitis virus B, e.g. the DNA obtained from the serum, tissue, cell, etc. of the patient affected with  hepatitis virus B is incised with a restriction enzyme (e.g. BamHI) to separate  the DNA into fractions containing the surface antigen gene in one side. The  DNA fraction containing the gene is inserted into a vector-DNA (e.g. pBR 322  DNA) to obtain the first recombinant. The recombinant is incised with another  restriction enzyme (e.g. TaqI) to obtain a DNA fraction containing a surface  antigen gene therein, and the fraction is inserted into the metabolic enzyme gene  of vector DNA having metabolic enzyme gene to obtain the objective recombinant for the synthesis of the surface antigen of hepatitis virus B.
PURPOSE: A composition for treating recurrent cancer or metastasis is provided to diagnose, suppress, and relieve recurrent cancer, or metastasis using XLR or XMR gene. CONSTITUTION: A composition for treating recurrent cancer or metastasis contains an antibody which specifically binds to SCP3(Synaptonemal complex protein 3), XLR(X-linked lymphocyte regulated protein), or XMR(Similar to xlr-related, meiosis regulated protein). A composition for treating recurrent cancer or metastasis contains immunocytes having epitopes of SCP3, XLR or XMR. The immunocyte is immunocytes transformed by a recombinant vector and epitope-sensitized immunocytes. The epitope has amino acid sequence of sequence numbers 35-40. The immunocytes are dendritic cell, T cell, NK cell, or B cell. A composition for treating recurrent cancer or metastasis contains siRNA, antisense, or shRNAi of SCP3, XLR or XMR.
The polynucleotides of the present invention are complementary to the Initiation Sites of microbes. Invading organisms, sensing the pH and nutrient deprivation of a physiologic environment quickly release these nucleotides triggering rapid growth and mutation—attributes to successfully establishing a nidus of infection. They also stimulate neutrophil functions. Accordingly, the nucleotides, compositions and methods of the present invention may be used to enhance, restore or stimulate an immune response or system of an animal, e.g. to prevent an infection caused by a microorganism, ameliorate an infection caused by a microorganism, or kill an invading microorganism that causes infection or re-establish balance to an immune system. In particular, the polynucleotides, compositions and methods of the present invention may be used to treat or prevent bacterial infections and auto-immune diseases in a mammal in need thereof.
The invention discloses a traditional Chinese medicine containing radix achyranthis bidentatae for treating facioplegia as well as a preparation method and a use thereof, which belong to the field of traditional Chinese medicines. The traditional Chinese medicine for treating facioplegia contains radix achyranthis bidentatae and honey with the ratio of weight parts of 1-30:1-30. The preparation method comprises the steps of: cleaning the traditional Chinese medicine, radix achyranthis bidentatae, drying, and then smashing into fine powder by a grinder, screening, sterilizing, adding honey according to the proportion, stirring evenly, then preparing preparations of various forms according to preparation method such as pill, granule, troche and the like which are convenient to take. Compared with the present medicine and method for treating facioplegia at home and abroad, the traditional Chinese medicine has the obvious advantages of no toxic or side effect, short course of treatment; symptomatic patients can recover completely after taking the medicine for 1-2 days, and at most a week. Operative patients can be thoroughly cured, and the cure rate of the traditional Chinese medicine for acute patients is 100 percent, thereby reducing the patient's anguish greatly and saving cost. After years of clinical verification, the traditional Chinese medicine has unique curative effect.
Immune cells undergo rapid and extensive metabolic changes during inflammation. In addition to contributing to energetic and biosynthetic demands, metabolites can also function as signaling molecules. Itaconate (ITA) rapidly accumulates to high levels in myeloid cells under infectious and sterile inflammatory conditions. This metabolite binds to and regulates the function of diverse proteins intracellularly to influence metabolism, oxidative response, epigenetic modification, and gene expression and to signal extracellularly through binding the G protein-coupled receptor (GPCR). Administration of ITA protects against inflammatory diseases and blockade of ITA production enhances antitumor immunity in preclinical models. In this article, we review ITA metabolism and its regulation, discuss its target proteins and mechanisms, and conjecture a rationale for developing ITA-based therapeutics to treat inflammatory diseases and cancer.
PROBLEM TO BE SOLVED: To obtain a new chain polyamine compound having carcinostatic action and useful as an active component for anticancer agent. SOLUTION: The objective compound is expressed by formula I [(n) is 1-8; R1 and R3 are each H or p-toluenesulfonyl; R2 and R4 are each ethyl or group of formula II ((m) is 1 or 2; R5 is H or p-toluenesulfonyl; R6 is H, ethyl, an aldehyde or cyclopropylmethyl or R5 and R6 together form a phthaloyl group)], e.g. 1,18-bis(ethylamino)-5,14-azaoctadecane. The compound of formula I is produced by reacting a compound of formula III with N2H2, reacting the produced compound in 2N-HCl and further reacting with TsCl in the presence of pyridine and NEt3 to obtain a tosylamide derivative of formula IV. In the case of introducing ethyl group, the product is reacted with a mixture of Et-Br and K2CO3. A detosylated compound can be produced by treating with 33% HBr-AcOH (acetic acid).
Participants will consume a 250cl bottle of soluble fibre-enriched kombucha mid-morning or mid-afternoon, avoiding consumption after eating. The drink will be included in a healthy eating plan. They will be advised to continue their usual physical activity during the 6 weeks of the study.
The invention discloses medicine composition for treating chronic active hepatitis and a preparation method of the medicine composition. The medicine composition for treating chronic active hepatitis comprises ingredients as follows: wild parsley, osbeckia crinita, Rubus saxatilis L., Eurya hebeclados Ling, scolopendra, Chinese brake herb, field sowthistle herb, clematis roots,  roots of champion pentasacme, Chinese wedelia herb, flabelate maiden-hair herb, roots of spine aralia, Meconopsis horridula Hook. f. et Thoms. var. racemosa (Maxim.) Prain., swertia punicea, all-grass of maidenhair, sida mysorensis, Iris tectorum Maxim., boor's mustard herb, abrus precatorius leaf extracts, Salvia prionitis Hance extracts and wallich eriophyton nano powder. Traditional Chinese medicines are reasonably selected according to clinical experience for elaborate preparation of the medicine composition; the medicine composition has the efficacy of liver soothing, spleen invigorating, detoxification, liver protection, liver calming for yang suppressing, heat clearing, diuresis, kidney tonification for yang strengthening, regulation of middle-warmer energy and qi tonification, can effectively repair injured cells of the liver, promote recovery of a cell regeneration function, has a remarkable treatment effect on chronic active hepatitis, is safe and does not have side effects, and the medicine property is mild.
<P>PROBLEM TO BE SOLVED: To provide a snore-preventing agent which exhibits a remarkably excellent snore-preventing effect in comparison with conventional products.  <P>SOLUTION: This snore-preventing agent is characterized by comprising a mixture which comprises coenzyme Q10, vitamin E and an emulsifier compound. The snore-preventing agent is preferably characterized by comprising a mixture which comprises 100 pts. wt. of the coenzyme Q10, 10 to 5,000 pts. wt. of the vitamin E and the emulsifier compound. The emulsifier compound is preferably a water-soluble polymer or a polyglycerol fatty acid ester. The snore-preventing agent is produced by adding the coenzyme Q10 and the vitamin E to an aqueous solution of the emulsifier compound and strongly stirring and emulsifying the mixture.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having at least one coating made at least in part using printing technologies to provide drug storage and drug release structures, notably for hydrophobic drugs and that such hydrophobic drugs can be stabilized as to hydrolysis, heat, and a combination thereof. A first aspect of the present invention includes a packaged medical device that includes at least one drug delivery contact lens. A second aspect of the present invention includes a drug delivery contact lens. A third aspect of the present invention includes a method of making a drug delivery contact lens. A fourth aspect of the present invention includes an ink. A fifth aspect of the present invention includes a method of using a drug delivery contact lens to treat or prevent a disease, disorder, or condition of the eye.
<P>PROBLEM TO BE SOLVED: To provide nucleotide sequences of a human Notch gene and Delta gene, and to provide an amino acid sequence of a protein for encoding the genes.  <P>SOLUTION: The nucleotide sequences of the human Notch gene and Delta gene, the amino acid sequence of the protein for encoding the gene, and its fragment which contains an antigenic determinant or is functionally active are provided, respectively. A fragment (referred to as "adhesion fragment") of a protein (referred to as "toporythmicprotein") encoded by a toporythmic gene which mediates homotypic or heterotypic bonding to a toporythmic protein and a sequence of the fragment are provided, respectively. The toporythmic gene comprises the Notch gene, the Delta gene, and a Serrate gene, and further comprises other members of the Delta/Serrate families, for example, which are identified by methods specified in the specification. Further, antibodies against the human Notch gene and the adhesion fragment are provided, respectively.  <P>COPYRIGHT: (C)2004,JPO
A phase II trial in human papillomavirus (HPV)-positive oropharyngeal squamous cell cancer (as determined by p16 immunohistochemistry with confirmatory ISH or PCR) to determine radiologic response to induction chemotherapy with nivolumab. Patients will undergo evaluation by a multidisciplinary team prior to risk assessment. The patients will be assigned to high or low risk groups based on tumor size, lymph node involvement, and smoking history. Patients will be assigned to treatment with induction chemotherapy with carboplatin, nab-paclitaxel, and nivolumab. Radiologic response to induction chemotherapy according to RECIST measurement of tumor shrinkage will then be used for therapeutic stratification of locoregional therapy, consisting of either transoral robotic surgery (TORS) or radiation with or without chemotherapy. Patients with low risk disease (see table above) and small volume tonsillar/BOT disease (T1-2 primary, non-bulky N2A-N2B nodal status) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS for primary site resection and selective nodal dissection as a definitive treatment if technically feasible with adjuvant radiation for adverse pathologic features. Patients with other low risk tumors e.g. with higher volume disease, or who refuse surgery, who also have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy (no chemotherapy). Patients with low risk features and \<50% but ≥30% reduction OR high risk features (T4, bulky N2B or N2C-N3, \>10 pack-years tobacco use) with ≥50% reduction will receive de-intensified chemoradiation with concurrent cisplatin-RT to 50 Gy (5 weeks) or TFHX to 45 Gy (3 cycles/6 weeks). Patients with low risk features and \<30% reduction OR high risk disease with \<50% reduction or any patients with progressive disease during induction chemotherapy will undergo chemoradiotherapy with concurrent cisplatin-RT to 70 Gy (7 weeks) or TFHX to 75 Gy (5 cycles/10 weeks). Patients with both high and low risk features who have ≥50% reduction will receive locoregional therapy targeting the pre-chemotherapy extent of disease only. Adjuvant nivolumab will be offered to all patients for 6-months post completion of definitive therapy (7 doses given as a flat dose of 480mg, every four weeks).